In the latest close session, AbbVie (ABBV) was up +1.65% at $281.04. This change outpaced the S&P 500's 0.06% loss on the day. Elsewhere, the Dow saw an upswing of 0.38%, while the tech-heavy Nasdaq depreciated by 0.44%.
Shares of the drugmaker have appreciated by 7.53% over the course of the past month, outperforming the Medical sector's gain of 0.04%, and the S&P 500's gain of 2.36%.
Market participants will be closely following the financial results of AbbVie in its upcoming release. The company plans to announce its earnings on October 30, 2026. The company is predicted to post an EPS of $3.8, indicating a 104.3% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $17.36 billion, up 10.01% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $13.98 per share and revenue of $67.63 billion, which would represent changes of +39.8% and +10.57%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for AbbVie. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.79% lower. Currently, AbbVie is carrying a Zacks Rank of #4 (Sell).
In terms of valuation, AbbVie is presently being traded at a Forward P/E ratio of 19.77. This signifies a premium in comparison to the average Forward P/E of 16.16 for its industry.
It's also important to note that ABBV currently trades at a PEG ratio of 1.26. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ABBV's industry had an average PEG ratio of 1.91 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 193, this industry ranks in the bottom 22% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).